Packaging of an AAV vector encoding human acid α-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector
Open Access
- 1 April 2003
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 7 (4) , 467-477
- https://doi.org/10.1016/s1525-0016(03)00022-4
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectorsGene Therapy, 2002
- A High-Capacity, Capsid-Modified Hybrid Adenovirus/Adeno-Associated Virus Vector for Stable Transduction of Human Hematopoietic CellsJournal of Virology, 2002
- Generation of Recombinant Adeno-associated Virus Vectors by a Complete Adenovirus-Mediated ApproachMolecular Therapy, 2001
- Recombinant adeno-associated virus purification using novel methods improves infectious titer and yieldGene Therapy, 1999
- QUANTIFICATION OF MURINE CYTOKINE mRNAs USING REAL TIME QUANTITATIVE REVERSE TRANSCRIPTASE PCRCytokine, 1999
- Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirusGene Therapy, 1999
- Novel Tools for Production and Purification of Recombinant Adenoassociated Virus VectorsHuman Gene Therapy, 1998
- High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle VirusHuman Gene Therapy, 1998
- Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapyGene Therapy, 1997
- Cell Lines for the Production of Recombinant Adeno-Associated VirusHuman Gene Therapy, 1995